Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K. Gupta, Ellen Koenig, Mezgebe Berhe et al.|The Lancet HIV|2022Cited by 107
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseasesNeha Dixit, Jonathan Zalevsky, Christie Fanton et al.|Journal of Translational Autoimmunity|2021Cited by 54
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J. Eron, Marina Caskey, Paul Cook et al.|The Lancet HIV|2024Cited by 47
Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in RodentsCaroline Machado Kopruszinski, Frank Porreca, Juliana Swiokla et al.|Cellular and Molecular Neurobiology|2020Cited by 10
In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic DevelopmentWendy Walwyn, Suchi Tiwari, Isabel Bishop et al.|Frontiers in Pain Research|2021Cited by 4